F8 and hemophilia A: Since both FVIII and bypassing agents account for more than 90 % of the direct medical care costs of hemophilia A (Café et al., 2019, Cortesi et al., 2018), the price and the consumed amount of these concentrates are the main determinants of the treatment cost.